(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
14 December 2023 (14.12.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/240082 A2

(51) International Patent Classification:
A61K 41/00 (2020.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/US2023/067996

(22) International Filing Date:
06 June 2023 (06.06.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/349,876 07 June 2022 (07.06.2022) US
63/405,243 09 September 2022 (09.09.2022) US

(71) Applicant: **INCYTE CORPORATION** [US/US]; 1801 Augustine Cut-Off, Wilmington, Delaware 19803 (US).

(72) Inventors; and
(71) Applicants: **HOYLE, Paul E.** [US/US]; c/o Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803 (US). **DONG, Zhiwan** [US/US]; c/o Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803 (US). **CONDAMINE, Thomas** [US/US]; c/o Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803 (US). **SRINIVASAN, Nithya** [US/US]; c/o Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803 (US). **JANIK, John E.** [US/US]; c/o Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803 (US). **HELLER, Kevin N.** [US/US]; c/o Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803 (US).

(74) Agent: **HANSON, Mark J.**; Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, 901 New York Avenue, NW, Washington, District of Columbia 20001-4413 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
— *with sequence listing part of description (Rule 5.2(a))*

WO 2023/240082 A2

(54) **Title:** COMBINATION THERAPY OF ANTI-PD-1 ACTIVE AGENT, ANTI-TIM-3 ACTIVE AGENT, AND ANTI-LAG-3 ACTIVE AGENT FOR TREATING CANCER

(57) **Abstract:** The present disclosure provides a combination therapy which comprises: (i) an active agent that binds PD-1 (*e.g.*, an anti-PD-1 antibody), (ii) an active agent that binds TIM-3 (*e.g.*, an anti-TIM-3 antibody), and/or (iii) an active agent that binds LAG-3 (*e.g.*, an anti-LAG-3 antibody). The present disclosure provides pharmaceutical compositions thereof, uses thereof, and methods of treatment which include administering the combination therapy to a subject, including methods of treating cancer.